Table 2.

Prevention of respiratory syncytial virus (RSV), passive immunization and new vaccines. Source Clinical trials.gov

Name	Mechanism	Remarks
Palivizumab (Synagis®)	Humanized monoclonal antibody that prevents	The most efficient and used antibody to cure or treat severe cases of RSV disease FDA approved
	RSV fusion to the host cells (passive immunization)
Motavizumab Medi-524	Humanized antibody that binds to fusion protein after attachment to the host cell (passive immunization)	Safety, Tolerability and Immunogenicity of MEDI-524 After Dosing for a Second Season complete Phase 1-III, complete
DNA vaccines	RSV G protein construct	Induces neutralizing antibodies and balances the pulmonary T helper type 1 (Th1)/Th2 cytokines
NDV-F	Newcastle disease virus (NDV) vector plus F protein	Induces a high interferon-β response
rBCG-RSV	Bacillus Calmette–Guérin (BCG attenuated Mycobacterium bovis) modified to express RSV N and M2 RSV proteins	Induces a Th1 immune response specific against RSV
RSV Fusion protein particle vaccine	Trimers Form F protein Nanoparticles (Nanovax)	Safety study complete